România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

octapharma (ip) ltd. - combinatii (factori de coagulare) - pulb+solv. pt. sol. perf. - 1000ui - vitamina k si alte hemostatice factori ai coagularii sanguine

Uniunea Europeană - română - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - hemostatice - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges m.b.h. - austria - combinatii (bioactive de coagulare) - pulb.+solv. pt. sol. perf. - 1000ui - vitamina k si alte hemostatice factori ai coagularii sanguine

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

octapharma pharmazeutika prod. ges.m.b.h. - austria - combinatii (bioactive de coagulare) - pulb.+solv. pt. sol. perf. - 500ui - vitamina k si alte hemostatice factori ai coagularii sanguine

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

generium sa - moroctocog alfa - pulbere şi solvent pentru soluţie injectabilă - 1000 ui/ 5 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

generium sa - moroctocog alfa - pulbere şi solvent pentru soluţie injectabilă - 250 ui/ 5 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

generium sa - moroctocog alfa - pulbere şi solvent pentru soluţie injectabilă - 500 ui/ 5 ml

România - română - Ecolab

ecolab deutschland gmbh -

Uniunea Europeană - română - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.